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The human complement system is one of the major effectors of
immune response and is involved in many cytolytic activities.
Autologous human cells, but not foreign cells, are usually
protected from this complement-mediated cytolysis by expressing
complement regulatory proteins (CRP) on their membranes
(Hourcade et al, 1989). The main CRP currently identified is
membrane cofactor protein (MCP, CD46), decay-accelerating
factor (CD55), Protection (CD59) and complement receptor 1
(CR1) (Davis et al, 1989; Hourcade et al, 1989; Lublin and
Atkinson, 1989; Lachmann, 1991; Liszewski et al, 1991).
MCP is composed of repeating units of approximately 60 amino
acids known as short consensus repeats (SCRs), a serine–threo-
nine–proline-rich region (STP) containing several O-linked glyco-
sylation sites, a transmembrane region, a basic amino acid anchor
and a cytoplasmic tail (Davis et al, 1989; Theodore et al, 1991;
Matsumoto et al, 1992). This CRP is widely distributed and is
expressed in fibroblast, endothelial cells and epithelial cells in
many organs including liver (McNearney et al, 1989; Liszewski
et al, 1991; Johnstone et al, 1993).
MCP serves as a cofactor for the plasma serine protease factor
I-mediated cleavage of C3b/C4b, the activated component of
complement cascade, and down-regulates the critical step of C3
activation. C3b, the activated form of C3, is induced via both the
classical pathway and an alternative pathway and activates the
terminal lytic complement sequence including the formation of the
membrane attack complex (Seya and Atkinson, 1989; Seya et al,
1994). Therefore, the down-regulation of C3b by MCP is crucial
for preventing autologous cells from complement-dependent
cytotoxicity.
In recent reports, increased expression of MCP was observed in
cells of human breast, stomach, colon, ovary, cervix and non-
small-cell lung cancer (Hofman et al, 1994; Inoue et al, 1994;
Niehans et al, 1996; Bjørge et al, 1997; Simpson et al, 1997).
Expression of MCP by tumours raises the possibility that the
complement system participates in host immune responses to
cancers. There are several in vitro experiments that support this
hypothesis; the number of CD55 molecules per cancer cell was
reported to correlate with the degree of complement resistance,
and the expression of MCP in CD55-negative cell lines protected
cells from complement-mediated lysis (Cheung et al, 1988; Seya
et al, 1990).
Liver produces complement components and expresses MCP
under normal conditions (Nagura et al, 1985; Scoazec et al, 1994),
but little is known about MCP expression in pathological condi-
tions of the liver, including human hepatocellular carcinoma
(HCC). In order to analyse the role of MCP in the development of
HCC, we examined the expression of MCP in various grades of
HCC as well as in non-cancerous liver tissue.
MATERIALS AND METHODS
Samples
Twenty-seven HCC samples (23 surgically resected, four autop-
sied), 27 corresponding adjacent non-cancerous livers (18 liver
cirrhosis, nine chronic hepatitis) and 12 normal livers were
studied. Morphologically and serologically normal liver samples
were obtained from autopsies of patients who died of cardiac
failure or lung diseases. Histological grades of HCC (eight well-
differentiated, 19 moderately differentiated) were determined
Expression of membrane cofactor protein (MCP, CD46)
in human liver diseases
N Kinugasa, T Higashi, K Nouso, H Nakatsukasa, Y Kobayashi, M Ishizaki, N Toshikuni, K Yoshida, S Uematsu and
T Tsuji
The First Department of Internal Medicine, Okayama University Medical School, 2-5-1 Shikata-cho, Okayama-city, Okayama 700-8558 Japan
Summary Membrane cofactor protein (MCP, CD46) is one of the complement regulatory proteins, and is widely distributed in human organs
and protects cells from complement-mediated cytotoxicity. We analysed the distribution and the intensities of MCP in liver diseases and
evaluated the role of MCP during hepatocarcinogenesis. Western blot analysis revealed that relative densities (density of the sample/density
of the standard sample) of MCP in 27 HCC, 18 liver cirrhosis, nine chronic hepatitis and 12 normal liver were 0.63 ± 0.23, 0.21 ± 0.07,
0.25 ± 0.10 and 0.11 ± 0.03 (mean ± s.d.) respectively. MCP expression in hepatocellular carcinoma (HCC) was significantly higher than that
in both liver cirrhosis and chronic hepatitis (P < 0.01). The difference in the tumour sizes, the grades of differentiation and viral marker status
did not affect the expression. Immunohistological analysis revealed that MCP was distributed mainly in the basolateral membrane of the
hepatic cord in non-cancerous liver, along with endothelial cells and bile duct cells. In HCC, the protein was observed on the membrane in a
non-polarized fashion. These data suggest that HCC cells acquire the increased MCP expression in a development of HCC and may escape
from tumour-specific complement-mediated cytotoxicity.
Keywords: membrane cofactor protein; hepatocellular carcinoma; liver; complement
1820
British Journal of Cancer (1999) 80(11), 1820–1825
© 1999 Cancer Research Campaign
Article no. bjoc.1999.0604
Received 16 September 1998
Revised 28 January 1999
Accepted 4 February 1999
Correspondence to: T HigashiExpression of MCP in human liver 1821
British Journal of Cancer (1999) 80(11), 1820–1825 © 1999 Cancer Research Campaign 
according to the criteria outlined by Liver Cancer Study Group
of Japan (Liver Cancer Study Group of Japan, 1989). Of the
27 patients, nine (33%) were women, and patients’ ages ranged
from 25 to 78 years (mean = 62.0 years). Six (22%) were positive
for hepatitis B virus surface antigen (HBs-Ag) and 14 (52%) were
positive for hepatitis C virus antibody (HCV-Ab). Informed
consent was obtained from all the patients for the experimental use
of the samples.
Tissue preparation
The samples were immediately frozen with dry ice after surgery or
autopsy and stored at –80°C until use. A part of each sample was
fixed with periodate–lysine–paraformaldehyde and embedded in
OCT compound (Lab Tek Products, Naperville, IL, USA) for
immunohistochemistry.
Western blot analysis
Frozen liver tissues were homogenized in 8 mM 3-[(3-cholamido-
propyl)-dimethylammonio]-1-propanesulphate in Tris-buffered
saline supplemented with 1 mM phenylmethyl sulphonyl fluoride
and allowed to solubilize for 30 min at 20°C. After incubation,
insoluble cell debris was removed by centrifugation at 100 000 g
for 30 min as previously reported (Simpson et al, 1993). Protein
concentration of the tissue extracts was determined using the
method of Bradford (1976). An equal amount of the protein
(20 mg) was separated by 12.5% sodium dodecyl sulphate-poly-
acrylamide gel electrophoresis under a non-reducing condition and
then transferred to a nitrocellulose membrane. The membrane was
blocked with 5% non-fat dry milk in phosphate-buffered saline
(PBS) containing 0.1% Tween-20, and incubated with mouse
monoclonal antibody against human MCP (J4-48, Immunotech,
Marseille-Luminy, France) diluted 1:1000 with PBS for 1 h at
room temperature. The blots were washed in PBS– Tween-20 and
then incubated with horseradish peroxidase-labelled anti-mouse
immunoglobulin (Amersham Japan, Tokyo, Japan) for 1 h at room
temperature. After washing with PBS– Tween-20, the membrane
was reacted with chemiluminescence solution (ECL Western blot-
ting detection system, Amersham Japan, Tokyo, Japan), and the
signal was visualized on autoradiography film. We used one of the
moderately differentiated HCC as the standard sample, which
showed the highest band intensity in a preliminary Western blot
study. The intensity of the signal was measured using a densito-
meter (Molecular Dynamics Scanning Imager 300SX) and was
defined as S(ODi), where ODi is the densitometer output (arbi-
trary units) above background at position i. The result was
expressed as relative density (density of the sample/density of the
standard sample). All experiments were performed in duplicate.
Immunohistochemistry
Six moderately differentiated HCC samples, corresponding non-
cancerous liver tissues and one normal liver tissue were examined
immunohistochemically. Tissue sections (4 mm) were cut in a
cryostat, placed on sialynized slides (DAKO, Tokyo, Japan)
and allowed to air-dry for 30 min. After rehydration in PBS,
endogenous peroxidase was destroyed by 3% hydrogen peroxide
treatment for 30 min and non-specific reactivity was blocked by
10-min incubation at room temperature with 10% normal rabbit
serum. The sections were reacted with monoclonal antibody
against human MCP (J4-48) diluted 1:1000 with PBS for 1 h at





























Figure 1 Western blot analysis of MCP. MCP expression in HCC (66 kDz,
53 kDz) was significantly higher than that in both liver cirrhosis and chronic
hepatitis. The normal liver showed the lowest degree of expression among
the groups examined (A). The band intensity was correlated with the amount
of a standard sample applied (B). The amount of protein and the
corresponding relative density were as follows: lane 1, 20 mg, 1.00; lane 2,
10 mg, 0.56; lane 3, 5 mg, 0.28; and lane 4, 2.5 mg, 0.06. HCC =
hepatocellular carcinoma, LC = liver cirrhosis, CH = chronic hepatitis, Normal
= normal liver
Figure 2 MCP expression in liver diseases. Significant differences were
observed between each group. Relative density = density of the
sample/density of the standard sample. HCC = hepatocellular carcinoma,
LC = liver cirrhosis, CH = chronic hepatitis, Normal = normal liver, *P<0.011822 N Kinugasa et al
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room temperature. Biotin-conjugated anti-mouse immunoglobulin
was used as the second antibody followed by a treatment with
peroxidase–streptavidin complex (Histofine, Nichirei, Japan). The
sections were stained with 30% 3,3¢-diaminobenzidine tetra-
hydrochloride (Histofine, Nichirei, Japan) and methyl green was
used for nuclear counterstaining. In each experiment, three
controls were always prepared: omission of the primary antibody,
incubation with an isotypic antibody, and incubation with normal
mouse serum.
Statistics
Statistical significance was evaluated by means of c2 test and
correlation between the size of HCC and MCP expression was
analysed by linear regression.
RESULTS
One or two MCP isoforms were expressed in each sample of liver
tissue. The molecular weights of the isoforms were approximately
53 kDa and 66 kDa, although subtle size differences existed
between each sample (Figure 1A). Individual variation of the ratio
of 66 kDa to 53 kDa was observed; however, the 66 kDa isoform
were predominant in all samples examined. The densitometric data
was well correlated with the amount of samples applied (Figure
1B). Relative density of total MCP components in HCC, liver
cirrhosis, chronic hepatitis and normal liver was 0.63 ± 0.23,
0.21 ± 0.07, 0.25 ± 0.10 and 0.11 ± 0.03 respectively (Figure 2).
MCP expression in HCC was significantly higher than that in
both liver cirrhosis and chronic hepatitis (P < 0.01). The normal
















































Figure 3 MCP expression in different grades of HCC. Well = well-
differentiated HCC, Mod = moderately differentiated HCC, NS = not
significant
Figure 4 MCP expression and hepatitis virus expression. HBV = HBs-Ag
positive, HCV = HCV-Ab positive. (l l) Chronic hepatitis and liver cirrhosis,

























Figure 5 MCP expression in different size of HCCs. No correlation between
MCP expression and the size of HCC was observed (r = 0.15)Expression of MCP in human liver 1823
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(P < 0.01). There was no significant difference in the expression of
MCP among different histological grades of HCC or the status
of hepatitis virus infection (Figures 3 and 4). The size of HCC did
not correlate with MCP expression (r = 0.15, Figure 5).
MCP expression was immunohistochemically detected in all six
HCC and corresponding non-cancerous livers (Figure 6A). MCP
was homogeneously distributed on the cellular membrane of
the hepatocyte in non-cancerous sections. The expression was
stronger on the basolateral membrane of the hepatic cords than on
the intercellular surface (Figure 6B). MCP was also detected in
sinusoidal endothelial cells, vascular endothelial cells, and a
strong expression was observed in bile duct cells (Figure 6C). In
HCC, the expression was stronger than in the non-cancerous tissue
in all cases examined. The main locus of the protein was the cell
membrane as was similarly observed in non-cancerous lesion.
MCP was observed in a non-polarized fashion in each cell, and the
cellular distribution of MCP was homogeneous in each trabeculum
of HCC (Figure 6D). MCP was expressed on the cellular
Figure 6 Immunostaining of MCP. Note that the expression in HCC (left lower side) was higher than that of liver cirrhosis (right upper side, ´100) (A). MCP
was expressed on the basolateral surface of hepatic cords in liver cirrhosis (´200) (B). Vascular endothelial cells and bile duct cells were stained with MCP
antibody (´200) (C). Strong expression of MCP was observed at the cell membrane of moderately differentiated hepatocellular carcinoma in non-polarized
fashion (´400) (D). Normal liver (´200) (E). The consecutive section of (D) was stained with normal mouse serum as a negative control (´200) (F). Methyl green






Fmembrane of the hepatocyte in normal liver as was observed in
non-cancerous tissue (Figure 6E). All controls were consistently
negative for staining (Figure 6F).
DISCUSSION
In this study, we first demonstrated that MCP is up-regulated in
chronically injured livers including HCC. CRP is necessary for
cells physiologically exposed to blood, such as erythrocytes and
vascular endothelial cells, to protect themselves against the
complement-dependent cytotoxicity. In contrast to the other
epithelial cells, hepatocytes are in intimate contact with blood
because of the fenestrated sinusoidal endothelium and the lack of
an organized basement membrane (Seya et al, 1990). Furthermore,
hepatocytes produce complement, and their sinusoidal membranes
are positive for C3 and C4 (Nagura et al, 1985). Recurrent necrosis
and regeneration of the hepatocyte that occur in chronic liver
diseases cause damage to liver function and lead to accumulation
of endotoxin, xenobiotics and immune complexes. Under these
conditions, hepatocytes may need to protect themselves from the
attack by complement by virtue of the increased expression of
MCP.
It has been recently reported that the increased expression of
CRPs, such as MCP, CD59, was observed in many human cancers
and carcinoma cell lines (Hakulinen and Meri, 1994; Hofman et al,
1994; Inoue et al, 1994; Mäenpää et al, 1996; Gorter et al, 1996;
Niehans et al, 1996; Bjørge et al, 1997; Simpson et al, 1997). The
expression of CD55 was also enhanced in the lumen of the
colorectal cancer glands (Inoue et al, 1994). In the present study,
the expression of the MCP in HCC was significantly higher than in
that of normal liver, chronic hepatitis and liver cirrhosis. CD55
and CD59 are two other major CRPs; however, our preliminary
study demonstrated that CD55 was not expressed in liver
parenchymal cells including HCC, and the enhancement of CD59
was not observed in most of the HCC (data not shown). Therefore,
it seems that MCP plays a major role in inhibiting the complement
activation in HCC.
The increase of MCP expression is an early event in the
progression of HCC, because the expression is enhanced in HCC
regardless of the size and the state of differentiation. There are
several possible reasons for MCP expression in HCC being much
higher than that in chronic hepatitis or liver cirrhosis. First, CH50 in
patients with HCC is higher than that in patients without HCC
(Matsumura et al, 1981). Hence, HCC cells that express high
amounts of MCP may be selected by immunological pressure
during tumour development. Second, MCP expression is known
to be up-regulated in human fetal liver (Simpson et al, 1993).
Therefore, MCP may be expressed with dedifferentiation of
hepatocytes during hepatocarcinogenesis.
Loss of polarity of the cells is frequently observed in many
neoplasms. However, the mechanism of the loss is not clear. The
cytoplasmic tail is the key to maintaining basolateral polarization
of MCP molecule. Isoforms containing cytoplasmic tail 1 are
transported to the cell surface more rapidly than their tail 2
counterparts and the deletion of the cytoplasmic tail abolishes this
polarized transport (Maisner et al, 1996). Our present immuno-
histochemical observation, in which HCC tended to lose the polar-
ization of MCP, may be caused by the deletion or mutation of the
cytoplasmic tail in HCC, although we could not detect clear size
differences of MCP by Western blotting analysis.
Further analysis is needed of MCP expression, differences with
the physiological roles of each isoform, and the polarization signal
of MCP in HCC. Eventually, the selective reduction of MCP
expression on the cell surface of cancer cells by antisense or
ribozyme may be an effective therapeutic strategy against HCC.
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